Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | State-of-the-art treatment regimens for LR-MDS

Valeria Santini, MD, University of Florence, Florence, Italy, gives an overview of the treatment landscape for lower-risk myelodysplastic syndromes (LR-MDS). Dr Santini talks on the role of imetelstat and luspatercept for patients with LR-MDS who are relapsed/refractory to erythropoiesis-stimulating agents (ESAs). In particular, Dr Santini comments on the potential use of luspatercept in patients with MDS who do not have ring sideroblasts, and highlights the efficacy of imetelstat in patients with SF3B1. Dr Santini also highlights evidence for the use of eltrombopag in patients with MDS and thrombocytopenia, and studies of lower doses of hypomethylating agents (HMAs). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.